3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
2
Active not recruiting
2
Terminated
1
Suspended
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
26
Carcinoma, Renal Cell
10
Melanoma
4
Urinary Bladder Neoplasms
3
Neoplasms
3
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Pancreatic Neoplasms
2
Kidney Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Radiation Injuries
1
Prostatic Hyperplasia
1
Penile Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Nocturia
1
Nephrolithiasis, Calcium Oxalate
1
Multiple Myeloma
1
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Metastatic Castrate Resistant Prostate Cancer
1
Mesothelioma
1
Interventions
talazoparib
1
CX 5461
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Suspended
×
Metastatic Castration Resistant Prostate Cancer (mCRPC)
×
Genitourinary
×
Clear all
NCT05425862
2023-12-11
REPAIR
Peter MacCallum Cancer Centre, Australia
Phase 1
Suspended
48 enrolled